153 related articles for article (PubMed ID: 25158930)
1. Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.
Huang CC; Tu SH; Lien HH; Huang CS; Huang CJ; Lai LC; Tsai MH; Chuang EY
Breast Cancer Res Treat; 2014 Sep; 147(2):353-70. PubMed ID: 25158930
[TBL] [Abstract][Full Text] [Related]
2. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
4. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
5. Population-based molecular prognosis of breast cancer by transcriptional profiling.
Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
7. A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.
Oh E; Choi YL; Park T; Lee S; Nam SJ; Shin YK
Breast Cancer Res Treat; 2012 Apr; 132(2):499-509. PubMed ID: 21667120
[TBL] [Abstract][Full Text] [Related]
8. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
[TBL] [Abstract][Full Text] [Related]
9. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
10. Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data.
Ahdesmäki M; Lancashire L; Proutski V; Wilson C; Davison TS; Harkin DP; Kennedy RD
Stat Appl Genet Mol Biol; 2013 Oct; 12(5):619-35. PubMed ID: 24077567
[TBL] [Abstract][Full Text] [Related]
11. [Claudins as prognostic factors of breast cancer].
Szász MA
Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
[TBL] [Abstract][Full Text] [Related]
12. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
14. A prognostic DNA signature for T1T2 node-negative breast cancer patients.
Gravier E; Pierron G; Vincent-Salomon A; Gruel N; Raynal V; Savignoni A; De Rycke Y; Pierga JY; Lucchesi C; Reyal F; Fourquet A; Roman-Roman S; Radvanyi F; Sastre-Garau X; Asselain B; Delattre O
Genes Chromosomes Cancer; 2010 Dec; 49(12):1125-34. PubMed ID: 20842727
[TBL] [Abstract][Full Text] [Related]
15. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of a 92-probe signature in breast cancer.
Akter S; Choi TG; Nguyen MN; Matondo A; Kim JH; Jo YH; Jo A; Shahid M; Jun DY; Yoo JY; Nguyen NN; Seo SW; Ali L; Lee JS; Yoon KS; Choe W; Kang I; Ha J; Kim J; Kim SS
Oncotarget; 2015 Jun; 6(17):15662-80. PubMed ID: 25883221
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.
Filleron T; Md FD; Kramar A; Spielmann M; Levy C; Fumoleau P; Canon JL; Martin AL; Roché H
Bull Cancer; 2013; 100(7-8):22-9. PubMed ID: 23822935
[TBL] [Abstract][Full Text] [Related]
18. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
20. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
